Hamed has 20+ years of experience as a technology focused operator. In 1997, he founded TIO Networks (TSXV:TNC) a kiosk solution provider and transitioned it into a multi-channel payment solution provider, specializing in bill payment and other financial services. In July of 2017, TIO Networks was acquired by PayPal (NASDAQ:PYPL) for CAD$304 million. Over his career, Hamed has gained extensive experience in strategic mergers, acquisitions, and divestitures, both as an operator (eg. TIO) and board member (eg. BBTV, WELL) with more than a dozen successful transactions.
CFA– Independent Director
Thomas has 15+ years of experience as a top ranked technology research analyst, working as a senior researcher for Yorkton Securities, Versant Partners, and Cantor Fitzgerald in Canada. Thomas is currently a managing partner at Difference Capital Financial, an organization that provides debt and equity growth capital to mainly late-stage private companies with a focus on technology, media, and healthcare. He also sits on the board of Mogo Finance Technology Inc. (TSX: MOGO). He served as the director for QHR Technologies Inc. (TSX-V: QHR) which was sold to Loblaw Companies Limited (TSX: L) in the fall of 2016 for +$170M.
John is a Toronto based businessman and award-winning Institutional investor for 20+ years with an extensive capital markets network. His investment focus has included companies from a variety of sectors, including technology, healthcare, and resources at various stages of development, ranging from early start-ups to Fortune 1000 Companies. John has both public and private company board experience and has participated in the WELL’s prior financings with his own personal capital.
Ken cofounded Cawkell Brodie LLP and has been a member of the BC Bar Association for thirty years. For 25+ years, he has been involved in various industries within public, private, and venture capital sectors. He is also a founder of Neurodyn Life Sciences Inc., a private biotech company focused on developing natural based products to treat Alzheimer’s and other neurodegenerative diseases.
Peter spent most of the last 30 years working as a director for several public companies where he has played a significant role in raising more than $100 million of equity capital. Peter is an economist by trade, having received his Master’s in Economics from New Brunswick University, and briefly working for the New Brunswick Provincial Government.